Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study

Objectives: To evaluate, in a multicentric Italian cohort of axial spondyloarthritis (axSpA) patients on Secukinumab (SEC) followed for 24 months: (1) the long-term effectiveness and safety of SEC; (2) the drug retention rate and low disease activity (LDA) measured as Bath Ankylosing Spondylitis Dis...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Roberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, Salvatore D’Angelo, Antonio Marchesoni, Carlo Salvarani, Ennio Lubrano, Luisa Costa, Ylenia Dal Bosco, Elena Fracassi, Augusta Ortolan, Mario Ferraioli, Antonio Carriero, Elisa Visalli, Riccardo Bixio, Francesca Desiati, Alberto Bergamini, Elisa Pedrollo, Andrea Doria, Rosario Foti, Antonio Carletto
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	SAGE Publishing 2022-04-01
Saila:	Therapeutic Advances in Musculoskeletal Disease
Sarrera elektronikoa:	https://doi.org/10.1177/1759720X221090310
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!